Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors

Cardiovascular Drugs and Therapy

Volumn 28, Issue 3, 2014, Pages 221-228

  Moore, Xiao Lei ^a   Su, Yidan ^a   Fan, Yingli ^a   Zhang, You Yi ^c   Woodcock, Elizabeth A ^a   Dart, Anthony M ^a,b   Du, Xiao Jun ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Adrenoceptors; Cardiomyocyte; Relaxin family peptide receptor 1 (RXFP1)

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; RECEPTOR; RELAXIN FAMILY PEPTIDE RECEPTOR 1; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; LGR7 PROTEIN, MOUSE; LGR7 PROTEIN, RAT; MESSENGER RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WILD TYPE; ANIMAL; DRUG EFFECTS; FEMALE; GENETICS; HEART VENTRICLE; MALE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; FEMALE; HEART VENTRICLES; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RNA, MESSENGER; UP-REGULATION;

EID: 84903769946     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6525-x     Document Type: Article

References (40)

1. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48-58.
2. Conrad KP. Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension. 2010;56:2-9.
3. Grossman J, Frishman WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18:305-12.
4. Zhang J, Qi YF, Geng B, et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides. 2005;26:1632-9. (Pubitemid 41169758)
5. Perna AM, Masini E, Nistri S, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005;19:1525-7. (Pubitemid 41279019)
6. Moore XL, Tan SL, Lo CY, et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology. 2007;148:1582-9.
7. Dschietzig T, Bartsch C, Kinkel T, et al. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann N YAcad Sci. 2005;1041:441-3. (Pubitemid 41132283)
8. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39.
9. Hernandez-Montfort JA, Arora S, Slawsky MT. Relaxin for treatment of acute heart failure: making the case for treating targeted patient profiles. Curr Heart Fail Rep. 2013;10:198-203.
10. Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors by the hormone relaxin. Science. 2002;295:671-4. (Pubitemid 34111824)
11. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev. 2013;93:405-80.
12. Osheroff PL, King KL. Binding and cross-linking of 32P-labeled human relaxin to human uterine cells and primary rat atrial cardiomyocytes. Endocrinology. 1995;136:4377-81.
13. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145:4125-33. (Pubitemid 39120561)
14. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
15. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.
16. 1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2011;51:518-28.
17. 1- adrenergic drive in pathological remodelling. Cardiovasc Res. 2008;77:452-62.
18. Moore XL, Hong A, Du XJ. α-adrenergic activation upregulates expression of relaxin receptor RXFP1 in cardiomyocytes. Ann N Y Acad Sci. 2009;1160:285-6.
19. 1A-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res. 2001;89:343-50.
20. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A. 1994;91:10109-13.
21. 2-adrenergic receptor. Science. 1994;264:582-6.
22. Liu Y, Gao XM, Fang L, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31:834-41.
23. Osheroff PL, Cronin MJ, Lofgren JA. Relaxin binding in the rat heart atrium. Proc Natl Acad Sci U S A. 1992;89:2384-8.
24. Scott DJ, Layfield S, Riesewijk A, Morita H, Tregear GW, Bathgate RA. Characterization of the mouse and rat relaxin receptors. Ann N Y Acad Sci. 2005;1041:8-12. (Pubitemid 41132220)
25. Yan W, Chen J, Wiley AA, Crean-Harris BD, Bartol FF, Bagnell CA. Relaxin (RLX) and estrogen affect estrogen receptor alpha, vascular endothelial growth factor, and RLX receptor expression in the neonatal porcine uterus and cervix. Reproduction. 2008;135:705-12. (Pubitemid 351676453)
26. Vodstrcil LA, Shynlova O, Westcott K, et al. Progesterone withdrawal, and not increased circulating relaxin, mediates the decrease in myometrial relaxin receptor (RXFP1) expression in late gestation in rats. Biol Reprod. 2010;83:825-32.
27. Noma T, Lemaire A, Nega Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-58.
28. Pereira L, Cheng H, Lao DH, et al. Epac2 mediates cardiac beta1-adrenergic-dependent sarcoplasmic reticulum Ca2+ leak and arrhythmia. Circulation. 2013;127:913-22.
29. Gong K, Li Z, Xu M, Du J, Lu Z, Zhang Y. A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors. J Biol Chem. 2008;283:29028-36.
30. Noor N, Patel CB, Rockman HA. Beta-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51:534-41.
31. Xu Q, Dalic A, Fang L, et al. Myocardial oxidative stress contributes to transgenic beta-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol. 2011;162:1012-28.
32. Kompa AR, Samuel CS, Summers RJ. Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol. 2002;137:710-8. (Pubitemid 35333097)
33. Dschietzig T, Alexiou K, Kinkel HT, Baumann G, Matschke K, Stangl K. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail. 2011;17:158-66.
34. Parikh A, Patel D, McTiernan CF, et al. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ Res. 2013;113:313-21.
35. Samuel CS, Du XJ, Bathgate RA, Summers RJ. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther. 2006;112:529-52. (Pubitemid 44486415)
36. Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. 2010;55:1260-6.
37. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182-90.
38. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation. 1993;87:IV90-6. (Pubitemid 23135655)
39. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler M. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570-8. (Pubitemid 24074931)
40. Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J. 2013;34:3128-36.